Pacer Advisors
BTAI icon

Pacer Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Pacer Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-104
Closed -$72K – 1432
2021
Q1 		$72K Sell
104
-88
-46% -$70.8K ﹤0.01% 1360
2020
Q4 		$142K Buy
192
+96
+100% +$74.8K ﹤0.01% 1291
2020
Q3 		$67K Buy
+96
New +$72.1K ﹤0.01% 1290

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Pacer Advisors's BTAI Position: Q2 2021 in Review

Pacer Advisors sold out of BioXcel Therapeutics (BTAI) in Q2 2021, closing a stake of 104 shares — an estimated $72K sold.

Pacer Advisors first reported a position in BTAI in Q3 2020 and held it in 3 quarters. The position peaked at $142K in Q4 2020. 108 funds tracked by Wall St. Rank hold BTAI as of Q2 2021.

  • Pacer Advisors reported no remaining BioXcel Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 104 BioXcel Therapeutics shares in Q2 2021, an estimated $72K.
  • Pacer Advisors first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 3 quarters.
  • Pacer Advisors's BioXcel Therapeutics position peaked at $142K in Q4 2020.
  • 108 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.